Liraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea.

Ellegaard AM, Kårhus ML, Krych L, Sonne DP, Forman JL, Hansen SH, Dragsted LO, Nielsen DS, Knop FK

Clinical and translational gastroenterology1 Nov 2024Cited by 5 (Europe PMC)

PMID39602188PMCIDPMC11596762DOI10.14309/ctg.0000000000000772PepBankPUB-39602188

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialMechanism
In patients with bile acid diarrhea, liraglutide induced a small increase in serum unconjugated bile acid concentrations.
In plain wordsIn people with bile acid diarrhea, liraglutide slightly raised unconjugated bile acids in the blood.
Peptide
Liraglutide
Outcome
IncreaseSerum unconjugated bile acid concentration
Study
n = 26
Outcome group
Metabolic pathways and metabolomics · Gastrointestinal
Studied dose
0.6 to 1.8 mg daily (uptitrated by 0.6 mg weekly) · subcutaneous · 6 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide induced a small increase in serum unconjugated bile acid concentrations
1 context sentence(design, population, supporting numbers)
Summary · context
or subcutaneously administered liraglutide (uptitrated by weekly increments of 0.6 mg from 0.6 to 1.8 mg daily, n = 26)
Report a problemFND-3960218801
02HumanRandomized controlled trialMechanism
In patients with bile acid diarrhea, liraglutide did not affect fecal bile acid concentrations.
In plain wordsIn people with bile acid diarrhea, liraglutide did not change bile acids in stool.
Peptide
Liraglutide
Outcome
No significant changeFecal bile acid concentration
Study
n = 26
Outcome group
Metabolic pathways and metabolomics · Gastrointestinal
Studied dose
0.6 to 1.8 mg daily (uptitrated by 0.6 mg weekly) · subcutaneous · 6 weeksAs given in this study (human).
Source sentences
Summary
without affecting fecal bile acid concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
or subcutaneously administered liraglutide (uptitrated by weekly increments of 0.6 mg from 0.6 to 1.8 mg daily, n = 26)
Report a problemFND-3960218802
03HumanRandomized controlled trialMechanism
In patients with bile acid diarrhea, no changes in fecal microbiota composition were observed with liraglutide or colesevelam.
In plain wordsIn people with bile acid diarrhea, gut bacteria in stool did not change with liraglutide or with colesevelam.
Peptide
Liraglutide
Outcome
No significant changeFecal microbiota composition
Study
n = 26
Outcome group
Gut microbiota · Gastrointestinal
Studied dose
0.6 to 1.8 mg daily (uptitrated by 0.6 mg weekly) · subcutaneous · 6 weeksAs given in this study (human).
Source sentences
Summary
No changes in fecal microbiota composition were observed with either treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
or subcutaneously administered liraglutide (uptitrated by weekly increments of 0.6 mg from 0.6 to 1.8 mg daily, n = 26)
Report a problemFND-3960218803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.